Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:approvalYear |
2018
|
| gptkbp:approvedBy |
gptkb:Japan
gptkb:United_States |
| gptkbp:ATCCode |
gptkb:G04BD15
|
| gptkbp:brand |
gptkb:Gemtesa
Beova |
| gptkbp:CASNumber |
1379753-27-9
|
| gptkbp:chemicalFormula |
https://pubchem.ncbi.nlm.nih.gov/compound/71251173
|
| gptkbp:developer |
gptkb:Urovant_Sciences
gptkb:Kyorin_Pharmaceutical |
| gptkbp:eliminationHalfLife |
60 hours
|
| gptkbp:excretion |
urine
feces |
| gptkbp:hasMolecularFormula |
C26H28F2N2O3
|
| https://www.w3.org/2000/01/rdf-schema#label |
vibegron
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
beta-3 adrenergic receptor agonist
|
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
454.51 g/mol
|
| gptkbp:pregnancyCategory |
Not assigned
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea headache hypertension |
| gptkbp:target |
gptkb:beta-3_adrenergic_receptor
|
| gptkbp:usedFor |
overactive bladder
|
| gptkbp:bfsParent |
gptkb:Urovant_Sciences
|
| gptkbp:bfsLayer |
6
|